TXA Study in Major Burn Surgery
Primary Purpose
Tranexamic Acid, Burn, Major Surgery
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Tranexamic Acid
Placebo Comparator
Sponsored by
About this trial
This is an interventional treatment trial for Tranexamic Acid focused on measuring Tranexamic Acid, Burn, Surgery, Tangential, Excision
Eligibility Criteria
Inclusion Criteria:
- Subjects undergoing burn excision surgery for standard of care purposes (to include: greater than or equal to 350 cm2 of full thickness or deep partial thickness burns)
- Male or female > 18 years of age
- Subject or subject's medical decision maker agrees to participate in this study and provides informed consent
Exclusion Criteria:
- Subjects with a history of hypercoagulopathy, deep vein thrombosis (DVT), pulmonary embolism
- Baseline creatinine level greater than 2.83 mg/dL
- Subjects with known hypersensitivity to tranexamic acid
- Patients with acquired defective color vision
- Patients with subarachnoid hemorrhage
- Children
- Pregnant women
- Prisoners
Sites / Locations
- Spectrum Health Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Tranexamic Acid
Placebo
Arm Description
1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
Placebo given over 10 minutes into the vein once prior to surgery
Outcomes
Primary Outcome Measures
Intraoperative Blood Loss in mL
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.
Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries.
Secondary Outcome Measures
Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival.
Full Information
NCT ID
NCT02753816
First Posted
April 18, 2016
Last Updated
August 20, 2021
Sponsor
Spectrum Health Hospitals
1. Study Identification
Unique Protocol Identification Number
NCT02753816
Brief Title
TXA Study in Major Burn Surgery
Official Title
The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Terminated
Why Stopped
Study enrollment and goals unable to be reached.
Study Start Date
April 2016 (undefined)
Primary Completion Date
December 3, 2019 (Actual)
Study Completion Date
December 3, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spectrum Health Hospitals
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and studied in patients undergoing open-heart surgery, liver transplantation, and urologic surgery. Investigators believe tranexamic acid may possibly decrease bleeding related to major burn surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your stay.
In this study, prior to each surgical procedure to treat the participants burn injury, the participant will receive either the drug tranexamic acid or placebo. The placebo is a liquid that looks like the tranexamic acid medicine, but does not have any active ingredient in it. In this study, both the tranexamic acid and the placebo are considered research.
Detailed Description
Neither the participant nor the study doctor will choose what treatment the participant gets. The participant will have an equal chance of being given the tranexamic acid or the placebo. Neither the participant nor the study doctor will know which treatment the participant is receiving.
The participant will receive one 1 gram dose of either tranexamic acid or placebo immediately before surgery. The dose of tranexamic acid or placebo will be given in the participants vein over a 10-minute period.
Information from the participants medical record related to their surgery and recovery time in the hospital will be collected by medical staff assisting with this study and recorded on study forms. These study forms will be labeled with the participants study number instead of their name.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tranexamic Acid, Burn, Major Surgery
Keywords
Tranexamic Acid, Burn, Surgery, Tangential, Excision
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tranexamic Acid
Arm Type
Experimental
Arm Description
1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo given over 10 minutes into the vein once prior to surgery
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Intervention Type
Drug
Intervention Name(s)
Placebo Comparator
Primary Outcome Measure Information:
Title
Intraoperative Blood Loss in mL
Description
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.
Time Frame
Intraoperative, average 122 minutes
Title
Blood Transfusion Rates, Defined Nominally (Binary) as Having at Least One Transfusion
Description
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries.
Time Frame
First burn surgery to hospital discharge
Secondary Outcome Measure Information:
Title
Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury
Description
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival.
Time Frame
Hospital admission to hospital discharge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects undergoing burn excision surgery for standard of care purposes (to include: greater than or equal to 350 cm2 of full thickness or deep partial thickness burns)
Male or female > 18 years of age
Subject or subject's medical decision maker agrees to participate in this study and provides informed consent
Exclusion Criteria:
Subjects with a history of hypercoagulopathy, deep vein thrombosis (DVT), pulmonary embolism
Baseline creatinine level greater than 2.83 mg/dL
Subjects with known hypersensitivity to tranexamic acid
Patients with acquired defective color vision
Patients with subarachnoid hemorrhage
Children
Pregnant women
Prisoners
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elizabeth Steensma, MD
Organizational Affiliation
Spectrum Health Hospitals
Official's Role
Principal Investigator
Facility Information:
Facility Name
Spectrum Health Hospital
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
6355500
Citation
Engrav LH, Heimbach DM, Reus JL, Harnar TJ, Marvin JA. Early excision and grafting vs. nonoperative treatment of burns of indeterminant depth: a randomized prospective study. J Trauma. 1983 Nov;23(11):1001-4. doi: 10.1097/00005373-198311000-00007.
Results Reference
background
PubMed Identifier
16414197
Citation
Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns. 2006 Mar;32(2):145-50. doi: 10.1016/j.burns.2005.09.005. Epub 2006 Jan 18.
Results Reference
background
PubMed Identifier
2357138
Citation
Desai MH, Herndon DN, Broemeling L, Barrow RE, Nichols RJ Jr, Rutan RL. Early burn wound excision significantly reduces blood loss. Ann Surg. 1990 Jun;211(6):753-9; discussion 759-62. doi: 10.1097/00000658-199006000-00015.
Results Reference
background
PubMed Identifier
21367529
Citation
Curinga G, Jain A, Feldman M, Prosciak M, Phillips B, Milner S. Red blood cell transfusion following burn. Burns. 2011 Aug;37(5):742-52. doi: 10.1016/j.burns.2011.01.016. Epub 2011 Mar 1.
Results Reference
background
Citation
Muller M, Gahankari D, Herndon DN. Operative wound management. Total burn care. 2007;3:177-195.
Results Reference
background
PubMed Identifier
4890296
Citation
Vermylen J, Verhaegen-Declercq ML, Fierens F, Verstraete M. A double blind study of the effect of tranexamic acid in essential menorrhagia. Bull Soc R Belge Gynecol Obstet. 1968;38(5):385-90. No abstract available.
Results Reference
background
PubMed Identifier
6159375
Citation
Prentice CR. Basis of antifibrinolytic therapy. J Clin Pathol Suppl (R Coll Pathol). 1980;14:35-40. No abstract available.
Results Reference
background
PubMed Identifier
25155138
Citation
Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014 Nov;29(11):2113-6. doi: 10.1016/j.arth.2014.07.019. Epub 2014 Jul 30.
Results Reference
background
PubMed Identifier
17090725
Citation
Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother. 2006 Dec;40(12):2205-10. doi: 10.1345/aph.1H295. Epub 2006 Nov 7.
Results Reference
background
PubMed Identifier
16436767
Citation
Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 Jan 26;354(4):353-65. doi: 10.1056/NEJMoa051379.
Results Reference
background
PubMed Identifier
21702233
Citation
Williams-Johnson JA, McDonald AH, Strachan GG, Williams EW. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. West Indian Med J. 2010 Dec;59(6):612-24.
Results Reference
background
Citation
Jennes S, Degrave E, Despiegeleer X, Grenez O. Effect of tranexamic acid on blood loss in burn surgery: A preliminary study: 33. Journal of Burn Care & Research. 2003;24:S59.
Results Reference
background
PubMed Identifier
21983540
Citation
Tang YM, Chapman TW, Brooks P. Use of tranexamic acid to reduce bleeding in burns surgery. J Plast Reconstr Aesthet Surg. 2012 May;65(5):684-6. doi: 10.1016/j.bjps.2011.09.028. Epub 2011 Oct 7.
Results Reference
background
PubMed Identifier
25116268
Citation
Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014 Aug 12;349:g4829. doi: 10.1136/bmj.g4829.
Results Reference
background
PubMed Identifier
25084492
Citation
Satahoo SS, Parikh PP, Naranjo D, Davis JS, Duncan RC, Pizano LR, Namias N, Schulman CI. Are burn patients really at risk for thrombotic events? J Burn Care Res. 2015 Jan-Feb;36(1):100-4. doi: 10.1097/BCR.0000000000000093.
Results Reference
background
Citation
Twisk JWR. Applied Multilevel Analysis: A Practical Guide for Medical Researchers. 2006. Cambridge University Press, London, UK.
Results Reference
background
Citation
American Burn Association. Burn incidence fact sheet. http://www.ameriburn.org/resources_factsheet.php. Accessed May 20, 2015.
Results Reference
background
Learn more about this trial
TXA Study in Major Burn Surgery
We'll reach out to this number within 24 hrs